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ABSTRACT 
Introduction: Among the several new strategies explored today to avoid the side effects in cancer chemotherapy. The concept of polymer-drug 
conjugates has shown considerable promise. In this context, genetically engineered long elastin like polypeptides (ELPs) have been examined 
recently as drug carriers. These ELPs, however, have certain limitations.  
Objective: It is our hypothesis that short synthetic ELPs can also be used as drug carriers so as to overcome these limitations. The purpose of this 
investigation was, therefore, to synthesize, characterize and evaluate a thermally responsive short ELP-Doxorubicin conjugate for targeted delivery. 
Methods: The ELP-Doxorubicin conjugate of molecular weight 1280 Da was synthesized and characterized by ESI-MS, FTIR and NMR studies. 
Turbidimetry, differential scanning calorimetry (DSC) and circular dichorism (CD) studies were carried out to evaluate its structural transition 
behavior. Cellular uptake and intracellular localization studies of the conjugate and the free drug were carried out by flow cytometry and confocal 
fluorescence microscopy, respectively. In vitro cytotoxicity of the conjugate was evaluated by the MTT assay method and compared with that of the 
free drug.  
Results: The results reveal that the short ELP synthesized exhibits structural transition behavior similar to naturally occurring long ELPs and 
delivers more drug molecules to intracellular space compared to the free drug. This structural transition behavior can also be exploited for targeting 
drugs to solid tumors using hyperthermia. 
Conclusion: As hypothesized our investigations clearly demonstrate that short thermally responsive ELPs are good carrier for targeting anticancer 
drugs to the intracellular space.  
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INTRODUCTION 
Mortality due to cancer is rising continuously the world over. 
Further, it is becoming very clear that the objective of developing 
specific low molecular weight drugs capable of preventing tumor 
growth without causing non-specific side effects is not possible [1]. 
Approaches are, therefore, being made today to improve the existing 
therapies like identifying new tumor specific molecular targets 
through genomics and proteomics and developing innovative drug 
delivery systems to target drugs to tumor cells and away from sites 
of toxicity in addition to maintaining the therapeutic concentration 
of drugs over long periods of time [2-5].  
Among the several new strategies of drug delivery systems being 
developed today, the concept of polymer-drug conjugates has shown 
considerable promise. Several of these conjugates are in different phases 
of clinical trials for various cancers [6]. In this context, genetically 
engineered long elastin like polypeptides (ELPs) have also been 
examined as drug carriers. These are pentapeptide repeats of Val-Pro-
Gly-Xaa-Gly amino acids (VPGXaaG)n
In all these investigations, genetically engineering techniques have 
been used for synthesizing the ELPs. This technique, however, is 
cumbersome and expensive. The presence of reactive side chain in 
these ELPs also makes them unstable over long periods of time and 
at higher temperatures. There is a need, therefore, to develop more 
versatile chemical approaches that require fewer synthetic steps. In 
this context, it is our hypothesis that short synthetic ELPs can also 
be used as drug carriers. They offer the possibility of higher amounts 
of drug conjugation. Further, it has been shown that short synthetic 
ELPs also undergo ITT behavior like genetically engineered long 
ELPs thus showing that pentameric repeat units are not always 
necessary for this behavior [17-18]. A detailed literature survey, 
however, revealed that such short synthetic ELPs, have not been 
investigated so far for developing and evaluating their drug 
conjugates. 
, where Xaa is a guest residue 
(except Pro) and n may vary from 10 to 200. These peptides are 
biocompatible, biodegradable, non immunogenic and can retain in blood 
circulation for longer times [7-12]. In addition to passively targeting to 
tumors by the enhanced permeable and retention (EPR) effect, they also 
show improved cytotoxicity in multidrug resistant cell lines compared to 
the free drug because of their longer plasma half-lives [13]. Another 
important feature of ELPs is their capability to undergo inverse 
temperature transition (ITT) behavior, which can be exploited by the 
application of external hyperthermia to induce these to localize in 
tumors. Investigations have, therefore, been carried out using genetically 
engineered ELPs for developing ELP-drug conjugates [14-16].  
The aim of the present investigation was, therefore, to synthesize a 
short ELP, namely GVGVPGVG, and evaluate its potential for 
targeted delivery of anticancer drugs by in vitro methods. 
Doxorubicin (Dox) was selected for conjugation as it is commonly 
used in the treatment of a wide range of cancers, hematological 
malignancies, many types of carcinoma and soft tissue sarcomas 
[19-20]. The mode of action of Dox is to block the synthesis of DNA 
by intercalating into the DNA strand and inhibit DNA 
topoisomerase II synthesis. Further, the C-13 position of Dox can 
be exploited for linking the short ELP through an acid labile 
hydrolyzable linkage, namely hydrazone (C=N-NH). A hydrolysable 
linkage is important for releasing the drug inside the lysosomal 
compartments of the cell. Water soluble polymeric drug 
conjugates are known to be taken in by cells by pinocytosis and 
trafficked via the endosomal compartments to the lysosomal 
compartments. The lysosomal enzymes at their acidic pH 
hydrolyze the acid sensitive hydrazone bond of the ELP-Dox 
conjugate and liberate the free drug, Dox. The free drug will then 
diffuse from the lysosomes into the cytoplasm and cause cell 
lysis/apoptosis. 
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MATERIALS AND METHODS  
Rink amide (amino methyl) polystyrene resin (loading capacity ~1.0 
mmol/g), Fmoc-Val, Fmoc-Gly and Fmoc-Pro-OH, succinic anhydride, 
triple distilled water, PBS and acetonitrile were procured from 
Fluka. Piperidine, HoBt, DIC, and diethyl ether were obtained from 
Spectrochem. Triisopropyl silane, 1-2 ethanedithiol, phenol, 
ninhydrin, trifluroacetic acid, anhydrous methanol, Fmoc hydrazide, 
Dox (>99%), Dulbecco’s Minimum Essential Medium (DMEM), 
penicillin G, streptomycin, nystatin, dimethyl sulfoxide (DMSO), 
dihydroethidium (DHE), DMSO d6 were procured from Sigma 
Aldrich.  
General methods 
1H NMR and 13
LC-
C NMR spectra were recorded on Bruker 400 
spectrometer. ESI-MS was performed on Micromass Q-TOF mass 
spectrometer electron spray ionization mode. IR spectra were 
recorded by FTIR model Thermo-iCAP 6000 Series. High 
performance liquid chromatography (HPLC) was performed on 
2010HT - Shimadzu system, using aqueous acetonitrile solution 
containing 0.05% TFA as a mobile phase and C-18 column, 4.6X250 
mm Kromasil C-18 column. Sample solution was eluted with a linear 
gradient of aqueous acetonitrile at a flow rate of 1 ml/min and 
detected by UV absorbance at the wavelength 220 nm. The HPLC 
purified samples were subjected to lyophilization to remove the 
excess solvent with the help of ALPHA 1-2 LD lyophilizer.  
A short ELP, H-Gly4-Val3-Gly3-Val2-Pro1-Gly2-Val1-Gly1-NH2,  was 
synthesized by Merrifield solid phase peptide synthetic technique 
using Fmoc chemistry on rink amide (amino methyl) polystyrene 
resin (loading capacity ~1.0 mmol/g) as shown in Scheme 1. The 
Fmoc group was deprotected from the last coupled amino acid, 
namely Gly4
 
 using 20% piperidine solution. Succinic anhydride was 
then added to obtain the succinic anhydride derivative of the ELP. 
The Fmoc hydrazide was added to the succinic anhydride derivative 
to obtain the ELP-hydrazide. Cleavage of the peptides from the resin 
and their precipitation and purification by reverse phase HPLC were 
achieved by standard procedures [21].  
1-2 ml dried DCM 
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Scheme 1: Solid phase peptide synthesis of short ELP 
 
ELP-hydrazide was then coupled to Dox via the acid sensitive 
hydrolysable hydrazone linkage at the C-13 position of Dox as 
shown in Scheme 2. Dox (0.0017 mmol) and ELP-hydrazide (0.0051 
mmol) were dissolved in anhydrous methanol. Trifluoroacetic acid 
was then added to catalyze the reaction. The reaction mixture was 
stirred at room temperature for 24 h while being protected from 
light. After 24 h the reaction was complete. The solvent was then 
removed under vacuum at room temperature. The residue was 
mixed with a small amount of methanol and placed in ultrasonic 
bath for 5 min. Chilled diethyl ether was added slowly when a red 
solid product, ELP-Dox conjugate, precipitated. It was collected by 
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Scheme 2: Solution phase coupling of Dox to the short ELP 
 
 
Structural characterization of the ELP, its derivatives and the ELP-
Dox conjugate was carried out by ESI-MS, FTIR, 1H NMR and 
[13]CNMR. The ITT of the short ELP was determined by measuring 
the optical turbidity of its aqueous solution as a function of 
temperature using Varion D spectrophotometer, Bio-Logic MOS-
450/AF, equipped with multi cell thermoelectric temperature 
controller. The purified ELP was dissolved in PBS buffer (1 M, pH= 
7.2) in the concentration range of 0.5-5 mg/ml. The turbidity profile 
was obtained by heating a 100 µm solutions of the ELP and 
measuring the transmission at 240 nm as a function of temperature 
at 20C/min heating scan rate.  
The physical and structural transition behavior of the short ELP was 
assessed by DSC and CD. A quantity of 20 µl (3.5 mg/ml) of the ELP 
solution in PBS (pH 7.2) was placed in a 40 µl aluminum pan of DSC 
(Mettler Toledo) and hermetically sealed. An equal volume of PBS 
(pH 7.2) was placed in the reference pan. The ELP was heated at a 
scanning rate of 20C/min from 250C to 1800C using calorimetric 
program consisting of a pre-equilibration phase at 200C for 20 min. 
The CD spectrum of the ELP (100 µm) in PBS at 7.2 pH was recorded 
on JASCO J-710 spectropolarimeter under constant nitrogen flush. 
CD scans were performed at three different temperatures, allowing 
the sample to equilibrate at each temperature for 5 min under 
constant nitrogen flush. The cuvette temperature was measured 
with Peltier equipped thermometer. The scans were collected using 
a spectral acquisition spacing of 0.5 or 1.0 nm (with 2.0 nm 
bandwidth) with an integration time of one second from 190 up to 
260 nm. Scans were processed on a computer and the average of 4 
runs was taken.  
The cerebral glioma cell lines (BMG-1; diploid, wild type p53) were 
cultured in Dulbecco’s Minimum Essential Medium (DMEM) with 5% 
foetal bovine serum containing the antibiotics, penicillin (100 
units/ml), streptomycin (50 units/ml) and nystatin (2 g/ml) in 
humidified 5% CO2 incubator at 370
The monolayer cell culture was trypsinized and the cell count 
adjusted to 5000 cells/200 µl/well. After 24 h, when a partial 
monolayer was formed, the supernatant was flicked off and the 
monolayer washed with the medium. Different concentrations of 
Dox and the ELP-Dox conjugate (5, 10, 20 50 100 μm each) were 
added to microtitre plates. The plates were then incubated at 37
C for in vitro MTT cell viability 
assay, flow cytometry and confocal fluorescence microscopy studies. 
0C 
for 3 days in 5% CO2 atmosphere. Microscopic examination was 
carried out and observations were noted every 24 h. The medium 
was discarded and 20 µl of MTT in PBS was added to each well. The 
plates were further incubated for 2 h while being protected from 
light at room temperature to solubilize the formazan formed. The 
absorbance was measured using a microplate reader at the 
wavelength of 540 nm. The percentage growth inhibition was 
calculated using formula,  
 
OD is the optical density measured at 540 nm. The experiment was 
performed twice.  
Flow cytometry was performed to quantify the relative fluorescence 
intensity of Dox and the ELP-Dox conjugate using various detectors. In 
order to check the membrane integrity of BMG-1 (diploid, wild type 
p53) cells, ~106 cells at log phase were mixed separately with the free 
drug, Dox and the ELP-Dox conjugate (100 µm) and incubated at 370C 
for 24 h with constant shaking. The cells were collected, washed twice 
with PBS in a petridish (5X106
In order to demonstrate the intracellular distribution of the 
fluorescent Dox and the ELP-Dox conjugate, BMG-1 cells were first 
grown on sterile glass cover slips in petridish (5X10
cells/dish) and resuspended in PBS for 
flow cytometric analysis under FACS LSR II flow cytometer. 
Fluorescence intensity of each cell was recorded and processed to 
obtain the histogram describing the distribution of the relative 
fluorescence unit (RFU) amongst the live cells. The free drug and the 
ELP-Dox conjugate treated cell groups along with the control group 
were analyzed. A gate corresponding to control cells was assigned 
based on the forward-scatter/side-scatter plot.  
6cells/dish). 
After 24 h, the cells were washed with serum free medium, treated 
separately with 100 µm of Dox and the ELP-Dox conjugate (prepared 
in DMEM serum free medium prior to use) and incubated at 370
The ESI-MS mass spectra showed molecular ion peak at m/z 640.04 
Da, 740.5 Da, 754.9 Da and 1280.4 Da consistent with the molecular 
formula C
C. At 
the end of the treatment, the cells were washed with PBS and 
examined under confocal fluorescence microscope and the images 
were captured using 40X objective.  
RESULTS AND DISCUSSION 
A thermally responsive short ELP was synthesized using solid phase 
peptide synthesis. Dox was successfully conjugated to the ELP via 
the hydrazone linkage at the C-13 position of Dox as outlined in 
Schemes 1 and 2.  
28H48N8O9, C32H53N9O11[M+1H], C32H55N11O10[M+1H] 
and C59H82N12O20[M+1H] 
 
for ELP, ELP succinic anhydride, ELP-
hydrazide and ELP-Dox conjugate, respectively (Table 1).  
Table 1: Molecular weights estimated by ESI-MS 
Sample Molecular Formula Expected Molecular  
Mass [M] (Dalton)  
Observed Molecular  
Mass (Dalton) 
ELP  C28H48N8O 640.73 Da  9 640.2 Da [M+1H] 
ELP-succcinic anhydride C32H53N9O 739.82 Da 11 740.5 Da [M+1H] 
ELP-hydrazide  C32H55N11O 753.85 Da 10 754.9 Da [M+1H] 
ELP-Dox conjugate C59H82N12O 1279.35 Da 20 1280.4 Da [M+1H] 
 
The series of characteristic IR bands obtained in FTIR spectra for Dox, 
ELP, ELP-hydrazide and ELP-Dox conjugate are summarized in Table 2. 
The data reveal a new band at 1653 cm-1
 
for the ELP-Dox conjugate that 
may be assigned to the stretching (υ C=N) vibrations which corresponds 
to the disappearance of Dox alkyl carbonyl group (C-13) and the 
formation of the drug conjugate with the new C=N linkage (Fig. 1).  
Table 2: Assignment of FTIR spectral peaks for ELP-Dox conjugate 
Sample IR Bands cm Description -1 
 
ELP-Dox conjugate 
3402 υ (N-H) 
3326 υ (H-O) 
2923 υ (C-H) 
1653 υ (C=N) 
1420 υ (C-N) 
1281 υ (C-O-C) 
1019 υ (C-C) 
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Fig. 1: FTIR spectra for ELP-Dox conjugate 
 
The 1HNMR data obtained are good in agreement for the structure of 
ELP-Dox conjugate: δ = 3.71 (d, J=8 Hz, 1H, Gly4 - α - CHa), 3.67 (d, 
J=8 Hz, 1H, Gly4 - α - CHb), 8.22 (t, J=4 Hz, 1H, Gly4 - α - NH), 0.80 (d, 
J=7.5 Hz, 3H, Val3 - γ - CH3a), 0.82 (d, J=7.5 Hz, 3H, Val3 - γ - CH3b), 
1.95 (m, 1H, Val3 - β - CH), 4.28 (dd, J=8 Hz, 1H, Val3 - α - CH), 8.21 
(d, J=4 Hz, 1H, Val3 - α - NH), 3.67 (d, J=8 Hz, 1H, Gly3 - α - CHa), 3.65 
(d, J=8 Hz, 1H, Gly3 - α - CHb), 8.20 (t, J=4 Hz, 1H, Gly3 - α - NH), 0.83 
(d, J=7.5 Hz, 3H, Val2 - γ - CH3a), 0.84 (d, J=7.5 Hz, 3H, Val2 - γ - 
CH3b),), 1.94 (m, 1H, Val2 - β - CH), 4.28 (dd, J=8 Hz, 1H, Val2 - α - 
CH), 7.91 (d, J=8 Hz, 1H, Val2 - α - NH), 4.13 (bt, J=8 Hz, 1H, Pro1 - α - 
CH), 1.94 (m, 2H, Pro1 - β - CH2), 1.88 (m, 2H, Pro1 - γ - CH2), 3.72 (t, 
J=8 Hz, 2H, Pro1 - δ - CH2), 3.67 (d, J=8 Hz, 1H, Gly2 - α - CHa), 3.65 
(d, J=8 Hz, 1H, Gly2 - α - CHb), 7.89 (t, J=8 Hz, 1H, Gly2 - α - NH), 0.87 
(d, J=7.5 Hz, 3H, Val1 - γ - CH3a), 0.89 (d, J=7.5 Hz, 3H, Val1 - γ - 
CH3b),), 1.97 (m, 1H, Val1 - β - CH), 4.28 (dd, J=8 Hz, 1H, Val1 - α - 
CH), 7.67 (d, J=8 Hz, 1H, Val1 - α - NH), 3.71 (d, J=8 Hz, 1H, Gly1 - α - 
CHa), 3.72 (d, J=8 Hz, 1H, Gly1 - α - CHb), 7.97 (t, J=8 Hz, 1H, Gly1 - α - 
NH), 3.60 (d, J=4 Hz, 2H, 21-H), 3.56 (d, J=4 Hz, 2H, 22-H), 7.81 (d, 
J=8 Hz, 1H, 4-H), 7.65 (d, J=8 Hz, 1H, 3-H), 7.67 (d, J=8 Hz, 1H, 2-H), 
5.42 (s, 1H, 1´-H), 5.29 (s, 1H, 8-OH), 4.30 (s, 1H, 10-H), 4.56 (s, 1H, 
5´-H), 4.13 (s, 1H, 4´-H), 3.98 (s, 1H, 1-OCH3), 3.72 (s, 1H, 3´-H), 2.42 
(dd, J=16Hz, 1H, 7-eqH), 2.40 (dd, J=16Hz, 1H, 7-axH), 2.14 (m, 1H, 
9-eqH), 2.37 (m, 1H, 9-axH), 1.82 (t, J=12Hz, 1H, 2´-eqH), 1.83 (t, 
J=12Hz, 1H, 2´-axH), 1.15 (s, 1H, 5´-CH3
 




HNMR for ELP-Dox conjugate 
The 13C NMR data obtained are in good agreement for the structure 
of ELP-Dox conjugate: δ = 160.82 (C-1), 119.04 (C-2), 134.16 (C-3), 
119.80 (C-4), 186.72 (C-5), 155.97 (C-6), 32.05 (C-7), 74.76 (C-8), 
32.05 (C-9), 74.76 (C-10), 155.97 (C-11), 188.82 (C-12), 155.97 (C-
13), 135.23 (C-14), 110.76 (C-15), 119.80 (C-16), 135.23 (C-17), 
110.69 (C-18), 135.23 (C-19), 99.13 (C-1´), 28.73 (C-2´), 46.59 (C-3´), 
66.13 (C-4´), 66.06 (C-5´), 57.74 (C-6´- OCH 3), 16.67 (C-7´-CH3), 
168.50 (C-20), 30.32 (C-21), 30.24 (C-22), 171.12 (C-23), 42.12 (Gly4 
- α - C), 170.94 (Gly4 - C=O), 19.11 (Val3 - γ - C), 29.08 (Val3 - β - C), 
58.23 (Val3 - α - C), 170.81 (Val3 - C=O), 42.12 (Gly3 - α - C), 170.81 
(Gly3 - C=O), 18.43 (Val2 - γ - C), 29.08 (Val2 - β - C), 58.23 (Val2 - α - 
C), 170.81 (Val2 - C=O), 66.65 (Pro1 - α - C), 28.15 (Pro1 - β - C), 
24.42 (Pro1 - γ - C), 47.23 (Pro1 - δ - C), 41.76 (Gly2 - α - C), 168.92 
(Gly2 - C=O), 18.20 (Val1 - γ - C), 29.18 (Val1 - β - C), 63.65 (Val1 - α - 
C), 169.98 (Val1 - C=O), 41.60 (Gly1 - α - C), 169.98 (Gly1 - C=O).  
13C NMR data also reveal that the chemical shift of the C-13 carbonyl 
carbon of Dox shifts from 214.42 ppm to 155.97 ppm thus 
confirming that Dox is coupled to the ELP via the hydrazone linkage 







C NMR for ELP-Dox conjugate 
 
Fig. 4: Turbidity profile for ELP (optical density at 240 nm) as a 
function of temperature 
 
The turbidity profile of the ELP as a function of temperature is 
shown in Fig. 4. The results reveal that the ELP is soluble in aqueous 
solution at 370C but as the temperature increases it starts 
aggregating above 400C, its ITT. Below its ITT the ELP is a clear 
solution but upon heating the solution becomes turbid because of 
the aggregation of the ELP. It exhibits a single narrow ITT over a 1-
20C range. The short ELP thus exhibits an ITT behavior near the 
physiological temperature (37±30
The DSC thermogram of the ELP is shown in Fig. 5. The figure 
indicates a clear visualization of the physical transition of the ELP. 
An exothermic peak near 40
C). 
0C observed denotes the peak 
temperature, Tp, which corresponds to the phase transition. The 
thermogram also shows a glass transition for the ELP at 970
 
C, 
corresponding to the degeneration of ELP at higher temperatures.  
 
Fig. 5: DSC thermogram for ELP 
 
 
The thermally induced structural transition behavior of the ELP was 
also examined by CD studies at three different temperatures, namely 
room temperature (270C), physiological temperature (370C) and ITT 
(400C). The CD spectra obtained is shown in Fig. 6. The spectra 
reveals that the short ELP at 100 µm concentration in PBS buffer of 
pH 7.2 undergoes a secondary structural transition with respect to 
temperature change. At 270C the CD spectrum consists of a large 
negative dip at 197 nm and a small shallow minimum dip at 220 nm 
corresponding to random structure of the ELP. As the temperature 
increases a shift in the band from 197 nm to 199 nm occurs, whereas 
the shallow minimum band at 220 nm increases concomitantly. The 
temperature dependent CD results are thus in good agreement with 
the existence of two main conformational states, namely one 
dominating at low temperatures consisting of random structure and 
the other prevailing at higher temperatures consisting of type II β 
turns. This behavior is similar to genetically engineered long ELPs.  
 
Fig. 6: CD spectra of short ELP at selected temperatures namely, 
room temperature, 270C, physiological temperature, 370C and 
ITT and physical transition temperature, 400
The short ELP-Dox conjugate and Dox were assayed for their ability 
to inhibit the growth of BMG-1 cerebral glioma cell lines. Cells 
treated with the ELP, Dox, the ELP-Dox conjugate and the control 
(nontreated cells) were allowed to grow in 96 well plates and 
quantified by measuring crystal violet staining or cellular 
metabolism of MTT. The results obtained are shown in Fig. 7. The 
results reveal that the ELP does not exhibit any intrinsic cytotoxicity. 
At 24 and 72 h, Dox and ELP-Dox conjugate show almost similar, 
approximately 42% and 78%, growth inhibition, respectively.  
C at a 
concentration of 100 µm in PBS at pH 7.2 
 
 
Fig. 7: Cytotoxicity effect of ELP, Dox and ELP-Dox conjugate on 
BMG-1 cell lines 
 
The cellular uptake of Dox and the ELP-Dox conjugate by BMG-1 
cerebral glioma cell line was measured using flow cytometry after 
24 h of Dox and ELP-Dox conjugate treatment and the results are 
shown in Fig. 8. The results reveal that both the free drug and ELP-
Dox conjugate are permeable to BMG-1 cerebral glioma cell line but 
show different intracellular uptake profiles. The control group 
(without the drug and the drug conjugate) does not show any drug 
uptake (Fig. 8a). The group treated with the free drug shows less 
drug uptake as compared to the group treated with ELP-Dox 
conjugate. The histogram of relative fluorescence per cell obtained 
from flow cytometry analysis and calculated relative fluorescence 
unit (RFU) of this distribution shows that the drug uptake by BMG-1 
cerebral glioma cell line is more for ELP-Dox drug conjugate treated 
group as compared to free drug treated group (Fig. 8b).  
The results of the RFU by flow cytometry are shown in Table 3. The 
results reveal an RFU of 100.7 for the free drug whereas when it is 
coupled to the ELP the RFU is 145 thus confirming that the drug 
uptake from ELP-Dox conjugate is more as compared to the free 
drug (Fig. 8c). The flow cytometry results thus reveal that the ELP 




Fig. 8: a. Total cell population b. Flow cytometry histograms showing the relative fluorescence of BMG-1 cells after free drug, Dox and ELP-
Dox conjugate treatment at 370C. c. Total cellular uptake of drug treated and ELP-Dox conjugate treated group as expressed in RFU 
Nanjan et al. 




Table 3: Cellular uptake measured by flow cytometry 
Description Concentration Relative fluorescence unit (RFU) 
Control group 100 µm 2.521 RFU 
Dox treated group 100 µm 100.7 RFU 
ELP-Dox conjugate treated group 100 µm 145.0 RFU 
 
The autofluorescence of the Dox flouorophore allows to visualize 
differences in intracellular localization after exposure of cells to the 
free drug, Dox and ELP-Dox conjugate. The data obtained on Olympus 
BX 60 fluorescence microscope are shown in Fig. 9. The data reveal 
that the fluorescence distribution in BMG-1 cells exposed for 100 µm 
Dox and ELP-Dox conjugate at 4 and 24 h incubation. At both 4 h and 
24 h incubation Dox accumulates at the nuclei whereas most of the 
ELP-Dox conjugate is located in either perinuclear region or cytoplasm 
initially with low fluorescence intensity. Further, on longer incubation 
a clear fluorescence localization was found for both the free drug as 
well as the drug conjugate. The results thus reveal that Dox targets the 
nucleus whereas the ELP-Dox conjugate targets distribution at the 
cytoplasm. Further, prolonged incubation of the free drug and ELP-
Dox conjugate leads to more cellular uptake intensity. The low 
molecular weight free drug, Dox and the high molecular weight ELP-
Dox conjugate thus show different cellular uptake mechanism.  
 
 
Fig. 9: Intracellular localization of free drug, Dox and ELP-Dox conjugate 
 
CONCLUSION 
The rationale for developing polymer-drug conjugate is to improve 
chemotherapy of anticancer drugs by overcoming some of their 
limitations. Our investigations reveal that a thermoresponsive 
short ELP-Dox conjugate can effectively deliver the anticancer 
drug, Dox to the intracellular space. Evidence for targeting 
specificity and cellular uptake of the drug from the ELP-Dox 
conjugate was obtained through confocal fluorescence microscopy 
and flow cytometry. It was also observed that coupling of Dox to 
the short ELP does not alter the toxicity profile of the drug. In 
summary, the present investigation clearly demonstrates that a 
short ELP is a good carrier for targeting anticancer drugs to the 
intracellular space. The present work should lead to newer 
polymeric drug conjugates for site-specific delivery of anticancer 
drugs with minimal side effects and thus improve cancer 
chemotherapy for human health.  
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Dulbecco's Modified Eagle Medium; Dox, Doxorubicin; ELP, Elastin 
like polypeptide; EPR, Enhanced permeability and retention; eq, 
equatorial; FACS, Fluorescence-activated cell sorting; Fmoc, 
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P/Pro, Proline; PBS, Phosphate Buffer Saline; RFU, Relative 
Fluorescence Unit; TFA, Trifluoroacetic acid; Tp
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